Assessing neurocognitive risks in children with solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the neurocognitive risks associated with solid tumors in children aged 6 to 16 years. It focuses on identifying factors that contribute to neurocognitive sequelae, including treatment types, tumor characteristics, and environmental influences such as socio-economic status. The study will utilize various assessment tools, including the WISC-V and NEPSY-II, to establish a scoring system for evaluating these risks. The goal is to better understand how these factors interplay and affect cognitive outcomes in young cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient aged 6 to 16 years and 11 months during the study period
* Type of pathology: solid tumor
* Place of treatment and follow-up: Gustave Roussy
* Minimum time from the end of the initial treatment:
* For patients who have not received treatment with methotrexate: 6 months
* For patients being treated with methotrexate: none
* Obtaining the non-opposition of parents / legal representatives
* Affiliation to a social security scheme.

Exclusion Criteria:

* Patients with other pathologies associated with mental retardation (autism, genetic syndrome ...)
* Patients lost to follow-up
* Deceased patients
* Patients treated for a pathology whose prognosis is involved in the very short term (infiltrating glioma of the brainstem, recurrence of the pathology during treatment)
* Non-French speaking patients

Where it's running

• Gustave Roussy
  Villejuif, Val De Marne, France Recruiting

Study contacts

• Study coordinator: Christelle DUFOUR, MD
• Email: christelle.dufour@gustaveroussy.fr
• Phone: +33 (0)1 42 11 42 11

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Fight Osteosarcoma with a European, evolving research platform from diagnosis to relapse

  A European platform trial in pediatric and young adult high-grade osteosarcoma will test Cabometyx as one treatment option while collecting tumor and blood samples to guide future strategies.

  Recruiting Phase 3 Gustave Roussy, Cancer Campus, Grand Paris · Aarhus and 76 other locations · NCT07871864

• Cohort for people with chronic myelomonocytic leukemia

  This project will collect blood and bone marrow samples from adults with chronic myelomonocytic leukemia at diagnosis and during disease changes to create an anonymized biobank researchers can use to test new questions.

  Recruiting Gustave Roussy, Cancer Campus, Grand Paris · Amiens and 23 other locations · NCT07512882

• ASP3082 for advanced KRAS G12D non-small-cell lung and pancreatic cancers

  This study tests whether the experimental drug ASP3082, given once-weekly by IV, helps people with advanced or metastatic non‑small‑cell lung cancer or pancreatic ductal adenocarcinoma that carry a KRAS G12D mutation.

  Recruiting at 6 sites Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, France and 6 other locations · NCT07483983

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Valemetostat for selected solid tumors with SWI/SNF gene alterations

  This trial will test whether valemetostat, an EZH1/2 inhibitor, can slow or stop growth in adults whose progressive solid tumors have specific SWI/SNF‑related gene changes.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif, Val de Marne and 3 other locations · NCT07303387

• Short-term preoperative elacestrant alone versus elacestrant plus ovarian suppression for premenopausal early-stage ER+/HER2- breast cancer

  We will test whether 4 weeks of elacestrant alone or with ovarian suppression lowers the tumor proliferation marker Ki67 in premenopausal women with stage I–II ER+/HER2- breast cancer.

  Recruiting Phase 2 Gustave Roussy, Cancer Campus, Grand Paris · Villejuif · NCT07159451

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.